# US 2025/0082820 A1 · Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082820 A1
- Document ID: US20250082820A1
- Status: Published application
- Kind: A1
- Application number: 18/607,924
- Filed: 2024-03-18
- Published: 2025-03-13
- Earliest claimed: 2016-08-24
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Xiaojie Yu; Darin J. Messina; Elizabeta Pavlovic; Cunqi Cui; Kate M. Smither
- Web page: https://patentgrep.com/patent/US20250082820A1

## CPC

- A61L 27/20: Polysaccharides
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08H 1/00: Macromolecular products derived from proteins (food proteins A23; glue, gelatine C09H)
- A61F 2/52: Mammary prostheses (brassieres with stiffening or bust-forming inserts A41C3/10, A41C3/14)
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/34: for soft tissue reconstruction
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08H: DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS (polysaccharides C08B; natural rubber C08C; natural resins or their derivatives C09F; bituminous materials C10)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.

## Claims

### Claim 1

A method of grafting fat in a soft tissue of a human subject, the method comprising:
(i) injecting a hydrogel component into the soft tissue of the subject, wherein the hydrogel component comprises water and a crosslinked macromolecular matrix, the crosslinked macromolecular matrix comprising a hyaluronic acid component and a silk fibroin component, wherein the hyaluronic acid component is crosslinked to the silk fibroin component by a multiamine cross linker; and
(ii) administering a fat component to the soft tissue of the subject, wherein the fat component contains a lipoaspirate; thereby increasing the volume of fat in the soft tissue of the human subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the injection of the hydrogel component and the administration of the fat component to the soft tissue is performed sequentially.

### Claim 3 (depends on 2)

The method of claim 2, wherein the injection of the hydrogel component to the soft tissue precedes the administration of the fat component to the soft tissue.

### Claim 4 (depends on 2)

The method of claim 2, wherein the fat component is injected into the soft tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein the multiamine cross linker comprises a diamine cross linker.

### Claim 6 (depends on 5)

The method of claim 5, wherein the multiamine cross linker is selected from the group consisting of a hexamethylene diamine (HMDA), lysine, lysine methyl ester, and lysine ethyl ester.

### Claim 7 (depends on 6)

The method of claim 6, wherein the multiamine cross linker is lysine methyl ester.

### Claim 8 (depends on 1)

The method of claim 1, wherein the silk fibroin is a B. mori silk fibroin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid to the silk fibroin in the range of about 25:1 to about 1:1.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hyaluronic acid component is present in the hydrogel component in a concentration of about 20 mg/mL to about 40 mg/mL, and wherein the silk fibroin component is present in the hydrogel component in a concentration of about 0.1 mg/mL to about 20 mg/mL.

### Claim 11 (depends on 10)

The method of claim 10, wherein the hyaluronic acid component is present in the hydrogel component in a concentration of about 9 mg/mL to about 32 mg/mL, and wherein the silk fibroin component is present in the hydrogel component in a concentration of about 1 mg/mL to about 8 mg/mL.

### Claim 12 (depends on 10)

The method of claim 10, wherein the hyaluronic acid component is present in the hydrogel component in a concentration of about 16 mg/mL to about 20 mg/mL, and wherein the silk fibroin component is present in the hydrogel component in a concentration of about 2 mg/mL to about 5 mg/mL.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hyaluronic acid component has a molecular weight of about 1,000,000 daltons to about 5,000,000 daltons.

### Claim 14 (depends on 1)

The method of claim 1, wherein the hyaluronic acid component has a molecular weight of about 1,000,000 daltons to about 3,000,000 daltons.

### Claim 15 (depends on 1)

The method of claim 1, wherein fat graft volume retention is increased as compared to administering the fat component alone.
